Lien Vo
Overview
Explore the profile of Lien Vo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
412
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Girard N, Besada M, Rogula B, Lucherini S, Vo L, Chaudhary M, et al.
Cancers (Basel)
. 2025 Feb;
17(4).
PMID: 39976394
Winifred W. Yu was not included as an author in the original publication [...].
2.
Girard N, Besada M, Rogula B, Lucherini S, Vo L, Chaudhary M, et al.
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001554
Background: This study aimed to estimate the relative efficacy of neoadjuvant nivolumab in combination with chemotherapy (neoNIVO + CT) compared to relevant treatments amongst resectable non-metastatic non-small-cell lung cancer (rNSCLC)...
3.
Waser N, Quintana M, Schweikert B, Chaft J, Berry L, Adam A, et al.
JNCI Cancer Spectr
. 2024 Mar;
8(3).
PMID: 38521542
Background: Surrogate endpoints for overall survival in patients with resectable non-small cell lung cancer receiving neoadjuvant therapy are needed to provide earlier treatment outcome indicators and accelerate drug approval. This...
4.
Provencio M, Carcereny E, Lopez Castro R, Calvo V, Abreu D, Cobo M, et al.
Transl Lung Cancer Res
. 2023 Nov;
12(10):2113-2128.
PMID: 38025806
Background: The burden of non-small cell lung cancer (NSCLC) remains high in Spain, with lung cancer accounting for 20% of cancer-related deaths annually. Programs such as the Spanish Thoracic Tumour...
5.
Nadler E, Vasudevan A, Wentworth C, Robert N, Penrod J, Fiore J, et al.
Future Oncol
. 2023 Sep;
19(26):1785-1800.
PMID: 37665271
Pathologic response has been shown to be a promising surrogate for survival in non-small-cell lung cancer. We examined the real-world relationship between these end points in patients with resectable stage...
6.
Amin A, Keshishian A, Hines D, Dina O, Le H, Rosenblatt L, et al.
Curr Med Res Opin
. 2022 Aug;
38(12):2131-2140.
PMID: 35993487
Objective: To provide an updated comparison of the risk and cost of stroke/systemic embolism (SE) and major bleeding between direct oral anticoagulants (DOAC: apixaban, rivaroxaban, dabigatran) and warfarin among non-valvular...
7.
Waser N, Vo L, McKenna M, Penrod J, Goring S
Future Oncol
. 2022 Jan;
18(12):1519-1530.
PMID: 35073732
The aim of this systematic literature review was to describe treatment patterns in nonmetastatic non-small-cell lung cancer. A search was conducted in MEDLINE and EMBASE. Eligible studies were multicentered (>50...
8.
Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, et al.
J Manag Care Spec Pharm
. 2020 Apr;
26(5):639-651.
PMID: 32347184
Objective: To compare hospitalization risks (all-cause, stroke/SE-related, and MB-related) and associated health care costs among elderly nonvalvular AF (NVAF) patients in the Medicare population who initiated warfarin, dabigatran, rivaroxaban, or...
9.
Weycker D, Li X, Wygant G, Lee T, Hamilton M, Luo X, et al.
Thromb Haemost
. 2020 Jan;
118(11):e1-e2.
PMID: 31986533
No abstract available.
10.
Trocio J, Rosen V, Gupta A, Dina O, Vo L, Hlavacek P, et al.
Clinicoecon Outcomes Res
. 2018 Dec;
11:23-49.
PMID: 30588051
Introduction: Direct oral anticoagulants (DOACs) have emerged as viable alternatives to traditional treatments such as vitamin K antagonists (VKAs) for venous thromboembolism (VTE). The objective of this review was to...